CJC-1295 Peptide Therapy
CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH). Researched for its extended half-life and sustained GH pulse amplitude.
/)
/)
What CJC-1295 may support
CJC-1295 was designed with a longer half-life than native GHRH, allowing less frequent dosing while maintaining GH pulse signaling. Two variants exist (with and without DAC); your doctor selects based on protocol goals.
Our team typically pairs CJC-1295 with a GHRP (such as Ipamorelin) for synergistic effect, and runs IGF-1 panels at intake and follow-up.
Patient experiences
The DAC version simplified things. Twice a week instead of daily, and labs every two months.
Combined with Ipamorelin from the start. Doctor walked me through why both, not one.
Steady protocol. No drama. Quarterly check-ins to adjust if needed.
Our solutions for Weight‑Loss Management
What BPC-157 is studied for
Indications evaluated in research, listed in order of current evidence weight. Suitability is determined case-by-case.
/)
What is CJC-1295?
CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH). Researched for its extended half-life and sustained GH pulse amplitude.
/)
How CJC-1295 may work
CJC-1295 is a synthetic GHRH analog stabilized for extended half-life. The longer pulse duration provides a steadier GH baseline compared with native GHRH or Sermorelin.
/)
Who it may be evaluated for
Adults wanting sustained GH support over longer cycles, especially when daily injection isn't practical. Lab confirmation precedes prescription.
/)
How Menscape prescribes CJC-1295
DAC or no-DAC variant chosen by the doctor based on protocol goals. DAC version dosed once or twice weekly; no-DAC version daily, usually paired with Ipamorelin.
Doctor-led evaluation
Every CJC-1295 protocol starts with a full medical consultation and history review.
Licensed compounding pharmacy
Prescriptions are filled by a licensed compounding pharmacy partner, not over-the-counter.
Monthly monitoring
Follow-up consultations every four to six weeks to assess response and safety.
Research-informed positioning
We frame CJC-1295 as a research-stage peptide and prescribe only when clinically appropriate.
CJC-1295 questions
What is CJC-1295 with DAC versus without DAC?
DAC (Drug Affinity Complex) extends the half-life to about a week. Without DAC, half-life is shorter. Your doctor selects based on protocol design.
How is CJC-1295 dosed?
DAC version: typically once or twice weekly. No-DAC: daily, often paired with Ipamorelin. Subcutaneous injection.
Is CJC-1295 FDA-approved?
No. CJC-1295 is a research peptide. Use is off-label and doctor-supervised.
Can CJC-1295 be combined with Ipamorelin?
Yes, this is the most common combination protocol. The two peptides act on different receptors and have a synergistic effect on GH release.
What lab tests do you run before starting?
Baseline IGF-1, hormone panel, fasting glucose, and lipid profile. We confirm that the HPG and somatotropic axes can respond to GHRH stimulation before prescribing.
Who should not use CJC-1295?
Patients with active malignancy, untreated pituitary or thyroid disorders, severe sleep apnea, or known hypersensitivity to GHRH analogs. Each case is reviewed during consultation.
Talk with our medical team about BPC-157
/)